Skip to content
Open access

Temporal Dynamics of PD-L1 Surface in RKO Cells: Characterizing the Reversible Impact of the Small-Molecule Dimerizer BMS-202

Jul 2026 · Biomedicines · Vol 14, pp. 1659 · 0 citations · 21 references
Medicine

TL;DR

These findings suggest that BMS-202-induced changes in surface PD-L1 are acute and reversible, with levels returning to baseline within 24 h post-exposure, and reveal a dynamic regulatory mechanism where small-molecule-induced dimerization triggers rapid protein trafficking and transient surface depletion.

Abstract

Background/Objectives. Programmed death-ligand 1 (PD-L1) is a critical immune checkpoint protein that enables tumors to evade immune surveillance by suppressing T cell activation. Monoclonal antibodies are currently used to modulate PD-1/PD-L1 interactions. However, several immune-associated adverse effects were ascribed to those treatments. This led to the necessity for small-molecule alternatives like BMS-202. Methods. In this study, we investigated the temporal dynamics of cell-surface PD-L1 in response to the small-molecule dimerizer BMS-202. Treatment with a non-cytotoxic concentration of BMS-202 at 5 µM triggered a transient reduction in surface PD-L1 concentration, reaching its lowest level at 15 min. In the attempt to characterize the fate of PD-L1 following exposure to the BMS-202 dimerizer, we employed a low-pH wash internalization assay. Results. The results demonstrated a transient increase in intracellular PD-L1 within 5–15 min of compound exposure, followed by rapid recovery of surface PD-L1 levels. These findings suggest that BMS-202-induced changes in surface PD-L1 are acute and reversible, with levels returning to baseline within 24 h post-exposure. Conclusions. These findings reveal a dynamic regulatory mechanism where small-molecule-induced dimerization triggers rapid protein trafficking and transient surface depletion. Understanding these temporal dynamics is essential for the development of next-generation small-molecule immune checkpoint inhibitors.

Read PDF

Similar papers

Aug 2026

Elucidating the mechanism of ADAM10/PD-L1 interaction in pancreatic adenocarcinoma cell lines using cellular and computational analyses.

This study elucidates the mechanism of ADAM10/PD-L1 interaction in the pancreatic adenocarcinoma cell line, PANC-1, using cellular assays, molecular docking, and molecular dynamics simulations to elucidate how ADAM10 recognizes and interacts with PD-L1, facilitating its cleavage.

Ahmed M. E. Abdalla, Yu Miao, Yasir A. Taha et al. · 0 citations
Open access Aug 2026

Multiple mechanisms regulate the nanoscale organization of PD-L1 at the cell surface

It is found that PD-L1 is organized into nanoscale clusters at the plasma membrane, with distinct regulatory roles for the actin cytoskeleton, galectin-3, and cholesterol within the plasma membrane of tumor cells.

Guus A. Franken, Abbey B. Arp, Dora Čerina et al. · 0 citations
Review Aug 2026

PD-1+/PD-L1+macrophages across diseases: a translational continuum from biomarkers to immunotherapeutic targets.

The regulatory mechanisms governing PD-1/PD-L1 expression in macrophages and their biological functions are summarized, the potential of PD-1+/PD-L1+ macrophages as prognostic biomarkers and therapeutic targets are discussed, and targeted intervention strategies for this macrophage subset are examined.

Jinjing Wu, Dan Zhou, Kunpeng Jiang et al. · 0 citations
Open access Sep 2026

Targeting the PD-L1-induced PDK4/GLS metabolic axis overcomes anti-PD-1 resistance in non-small cell lung cancer

This study identifies a novel ‘PD-L1–ER stress–pyruvate–macrophage senescence’ axis as a key mechanism underlying primary resistance to ICB and proposes that targeting the PDK4/GLS-dependent pyruvate surge offers a promising therapeutic strategy to sensitize tumors to anti-PD-1 immunotherapy.

Wen-Xin Lian, Hui Yang, Yu-Qi Zhang et al. · 0 citations
Open access Sep 2026

Quinine modulates PD-L1 and STAT3 in MCF-7 cells: An in silico and in vitro study

Findings indicate that quinine suppresses MCF-7 cell growth and migration by downregulating PD-L1 and STAT3 gene expression, reducing VEGF levels, and increasing TINAGL-1 levels, highlighting the compound’s potential for PD-L1 inhibition in cancer.

Fuat Karakuş, Sedat Köstekci, B. Kuzu et al. · 1 citation
Review Open access Aug 2026

[IUPHAR review] Resistance to PD-1/PD-L1 blockade: mechanisms and pharmacological strategies.

Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have transformed the realm of cancer treatment. Nevertheless, fewer than one in five patients derive durable benefit, and a substantial proportion of initial responders eventually relapse, reflecting a heterogeneous milieu of intrinsic and acquired mecha...

A. Kim, Nawon Lee, Hung-Yu Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.